Pricing
  1. JP-listed companies
  2. Kringle Pharma,Inc.
  3. Financials
  4. Income before tax

Kringle Pharma,Inc. (4884)

Market cap
¥2.7B
P/E ratio
-2.3x
Kringel Pharma develops treatments for rare diseases like spinal cord injury and ALS using recombinant human HGF protein technology for medical institutions and pharma partners.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Sep 30, 2025-915+21.17%
Sep 30, 2024-755-11.46%
Sep 30, 2023-853+158.12%
Sep 30, 2022-330+10.23%
Sep 30, 2021-300+157.58%
Sep 30, 2020-116-61.43%
Sep 30, 2019-302+370.31%
Sep 30, 2018-64-36.92%
Sep 30, 2017-102-199.98%
Sep 30, 2016102-151.41%
Sep 30, 2015-198

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat